US Pharma MarketingArrowhead’s brain-targeting drug lowers Alzheimer’s tau protein in early study
Arrowhead Pharmaceuticals Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s…
Arrowhead Pharmaceuticals has shown that a genetic medicine administered as a subcutaneous injection can seemingly travel into the brain and lower levels of tau, a protein implicated in Alzheimer’s disease.
The company found that the ...
Source: Endpoints News